Skip to Content
Merck
  • Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.

Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.

British journal of haematology (2017-04-19)
Prisca M J Theunissen, Lukasz Sedek, Valerie De Haas, Tomasz Szczepanski, Alita Van Der Sluijs, Ester Mejstrikova, Michaela Nováková, Tomas Kalina, Quentin Lecrevisse, Alberto Orfao, Arjan C Lankester, Jacques J M van Dongen, Vincent H J Van Der Velden
ABSTRACT

Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals. In this study, EuroFlow-based 8-colour flow cytometry and innovative analysis tools were used to first characterize the immunophenotypic maturation of normal BCPs in bone marrow (BM) from healthy children, resulting in a continuous multiparametric pathway including transition stages. This pathway was subsequently used as a reference to characterize the immunophenotypic maturation of regenerating BCPs in BM from children treated for BCP-ALL. We identified pre-B-I cells that expressed low or dim CD34 levels, in contrast to the classical CD34

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-Benzidino-6-(4-chlorophenyl)pyridazine, ≥98% (HPLC), solid